Study details
Enrolling now
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
University of California, San Diego
NCT IDNCT04883255ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
138
Study length
about 2.8 years
Ages
18–65
Locations
1 site in CA
About this study
Researchers are testing how different cannabis treatments affect cognitive functions like decision-making and attention in people with HIV. The trial will also measure levels of endocannabinoids (chemicals that interact with the body's natural cannabinoid system) to see if cannabis use impacts these systems.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take 10 mg Δ9-tetrahydrocannabinol (THC)
- 2.Take 600 mg cannabidiol (CBD)
- 3.Take Placebo
PhaseEARLY_Phase 1
Drug10 mg Δ9-tetrahydrocannabinol (THC)
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
dronabinol, cannabidiol, cannabinoid
Drug routes
oral (Oral Solution)
Body systems
Immune, Infectious